Tag: Andrew Harline
Structure Therapeutics raises USD180m in ADS offering
Biopharmaceutical company Structure Therapeutics raised USD134 million in a Nasdaq listing, offering 8.95 million American depositary shares (ADS) priced at USD15 each
Biopharmaceutical company Structure Therapeutics raised USD134 million in a Nasdaq listing, offering 8.95 million American depositary shares (ADS) priced at USD15 each
Following the US regulator's decision to deem a stablecoin unregistered security, Asian regulators may be better positioned to adopt the approach to ensure effective oversight